Related Experiment Videos
[What's new in dermatological treatment?]
1Service de dermatologie, Hôpital Bichat, université Paris 7, Paris, France.
Annales De Dermatologie Et De Venereologie
|December 26, 2018
Summary
The management of inflammatory skin diseases is rapidly advancing with new biologic therapies and small molecules for psoriasis, atopic dermatitis, and alopecia areata. Technological innovations, including RNA interference, also show promise for conditions like hereditary amyloidosis.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Inflammatory dermatoses management is undergoing significant transformation.
- Existing treatments are being augmented by novel therapeutic classes.
Purpose of the Study:
- To review the expanding therapeutic landscape for inflammatory dermatoses.
- To highlight emerging treatments for psoriasis, atopic dermatitis, alopecia areata, and hereditary amyloidosis.
Main Methods:
- Review of recent clinical trials and therapeutic advancements.
- Focus on biologic agents, small molecules, and RNA interference therapies.
Main Results:
- Psoriasis treatment options now include TNF blockers, anti-IL12/IL23, anti-IL17, anti-IL23 antibodies, and tyrosine kinase inhibitors.
- New biologics targeting IL-4/IL-13 are emerging for atopic dermatitis.
- JAK inhibitors show efficacy in alopecia areata and potential in dermatomyositis.
- Small interfering RNA demonstrates efficacy in hereditary amyloidosis.
Conclusions:
- A new era of targeted therapies is revolutionizing inflammatory dermatoses treatment.
- Biologics, small molecules, and RNA-based therapies offer improved outcomes and new hope for patients.